



ASX RELEASE

ISSUE OF OPTIONS

11 August 2017: - Race Oncology Limited (ASX: **RAC**) advises that following the share placement announced to the market on 17 July 2017, the Company has agreed to issue 2,000,000 unlisted options each to Merchant Capital Markets Pty Ltd and 708 Capital Pty Ltd, exercisable at \$0.30 each on or before 30 September 2018.

It is anticipated that these options will be issued pursuant to the Company's 15% capacity under ASX Listing Rule 7.1, subject to the resolutions to be put to the General Meeting to be held on 30 August 2017 being approved by shareholders.

About Race Oncology Limited

Race Oncology is a specialty pharmaceutical company, whose business model is to pursue later stage assets, principally in the cancer field. The Company's first asset is a chemotherapy drug, Bisantrane, which was the subject of more than 40 phase II clinical studies during the 1980s and 1990s. Race Oncology owns recent patent filings on Bisantrane and has secured Orphan Drug Designation in the US. The Company's goal is to complete development of Bisantrane and bring Bisantrane to market.

Information Contacts:

Race Oncology

Peter Webse, Company Secretary

E: peter.webse@pcscorporate.com.au

W: www.raceoncology.com